<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">24510743</PMID>
        <DateCompleted>
            <Year>2014</Year>
            <Month>09</Month>
            <Day>30</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1534-6269</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>16</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Apr</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Current oncology reports</Title>
                <ISOAbbreviation>Curr Oncol Rep</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Dangers of &quot;confirmatory&quot; cancer trials that fail to actually test the original hypothesis.</ArticleTitle>
            <Pagination>
                <MedlinePgn>381</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s11912-014-0381-5</ELocationID>
            <Abstract>
                <AbstractText>The concept of &quot;confirmatory&quot; studies is a standard and important component of the overall clinical trials strategy in oncology. However, it is critical that such studies are similar enough in basic design and how they are conducted that they actually have the realistic potential to confirm, or refute, objectively the findings of the original study. In this commentary, two examples of clinical studies in the gynecologic oncology arena suggested by some to serve as &quot;confirmatory&quot; trials for the original reports demonstrate both the dangers and potential inappropriateness of such conclusions. </AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Markman</LastName>
                    <ForeName>Maurie</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Cancer Treatment Centers of America, Philadelphia, PA, USA, Maurie.Markman@ctca-hope.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Curr Oncol Rep</MedlineTA>
            <NlmUniqueID>100888967</NlmUniqueID>
            <ISSNLinking>1523-3790</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010051" MajorTopicYN="N">Ovarian Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName>
                <QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012107" MajorTopicYN="N">Research Design</DescriptorName>
                <QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>2</Month>
                <Day>11</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>2</Month>
                <Day>11</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>10</Month>
                <Day>1</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">24510743</ArticleId>
            <ArticleId IdType="doi">10.1007/s11912-014-0381-5</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Gynecol Oncol. 2009 Aug;114(2):195-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19447479</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gynecol Oncol. 2006 Jun;101(3):436-40</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16325893</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2009 Oct 1;27(28):4642-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19704064</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2003 Jul 1;21(13):2460-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12829663</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet. 2009 Oct 17;374(9698):1331-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19767092</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet Oncol. 2013 Sep;14(10):1020-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23948349</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gynecol Oncol. 2004 Mar;92(3):813-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14984946</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>
